OncoLink Cancer Treatment and Resources

Oncolink Features

Find My Cancer Drug

OncoLink Cancer Treatment and Resources

Tipos de Cancer / Leucemia / Leucemia de Célula Pilosa / Recursos de NCI

Link to OncoLink

NCI CANCERLIT^® Search: Hairy Cell Leukemia - October 2001

Imprima English

National Cancer Institute^®
Ultima Vez Modificado: 21 de noviembre del 2001

Guillain-Barre syndrome following 2-chlorodeoxyadenosine treatment for Hairy Cell Leukemia.

Clonal chromosome rearrangements in hairy cell leukemia: personal experience and review of literature.

[European-American-type hairy cell leukemia without splenomegaly, treated successfully with deoxycoformycin]

Remember mycobacterial disease in hairy cell leukaemia (HCL).

Patient sues UCLA over patent on cell line.

Patient sues for title to own cells.

Outrageous fortune: selling other people's cells.

Hypocholesterolaemia in hairy cell leukemia.

[Successful treatment of hairy cell leukemia with pentostatin]

Table of Contents

1
UI - 21240496
AU - Sarmiento MA; Neme D; Fornari MC; Bengio RM
TI - Guillain-Barre syndrome following 2-chlorodeoxyadenosine treatment for Hairy Cell Leukemia.
SO - Leuk Lymphoma 2000 Nov;39(5-6):657-9
AD - Department of Clinica Hematologica, Instituto de Investigaciones Hematologicas Mariano R. Castex. Academia Nacional de Medicina de Buenos Aires, Argentina.
A 68-year-old man, with Hairy Cell Leukemia developed a Guillain-Barre syndrome (G-B), 32 days after a single course of 2-Chlorodeoxyadenosine (CDA) at 0,14 mg/k/d, for five days in a two-hour-i.v. infusion and following a febrile neutropenia episode. In order to clarify whether this G-B case was related to an infection or to CDA neurotoxicity, we screened for infection-related autoimmune G-B and for antibodies (abs.) against gangliosides of peripheral nerves. Blood and urinary cultures were negative as well as serum anti-virus abs. However, serum anti-ganglioside abs. were positive for anti-asialo GM1 and anti-Gd1b. This latter finding was consistent with an autoimmune mechanism, not described until now as CDA neurotoxicity. In the present case, we do not have enough evidence to link CDA administration to the G-B syndrome. We think that it is necessary to exclude other causes of neurotoxicity before considering CDA adverse effect.

2
UI - 21450462
AU - Sambani C; Trafalis DT; Mitsoulis-Mentzikoff C; Poulakidas E;
TI - Makropoulos V; Pantelias GE; Mecucci C Clonal chromosome rearrangements in hairy cell leukemia: personal experience and review of literature.
SO - Cancer Genet Cytogenet 2001 Sep;129(2):138-44
AD - Laboratory of Health Physics & Environmental Hygiene, I/NT-RP, NCSR "Demokritos," 153 10 Aghia Paraskevi, Athens, Greece. csambani@mail.demokritos.gr
Cytogenetic studies in hairy cell leukemia (HCL) are rare. In the present report, cytogenetic investigations were performed on marrow cells obtained from 21 HCL male patients with a mean age of 57 years and active disease. Karyotypic analysis was successful in 18 of the 21 patients, either at diagnosis or in relapse after treatment with IFNa. Clonal chromosome abnormalities were detected in eight of 18 cases. The chromosome most frequently involved in the rearranged karyotypes was chromosome 14. Results are discussed with respect to 79 abnormal HCL cases obtained from an extensive review of the literature from 1978 to 2000.

3
UI - 21346282
AU - Muta T; Okamura T; Oshima K; Kikuchi M; Niho Y
TI - [European-American-type hairy cell leukemia without splenomegaly, treated successfully with deoxycoformycin]
SO - Rinsho Ketsueki 2001 May;42(5):426-31
AD - Department of Internal Medicine, Chihaya Hospital.
A 55-year-old Japanese man was hospitalized on October 5, 1999, because of high fever. Physical examination revealed neither lymphadenopathy nor hepato-splenomegaly. Laboratory data on admission showed a white blood cell count of 1,580/microliter, a hemoglobin level of 9.1 g/dl, and a platelet count of 113 x 10(3)/microliter. A small percentage of abnormal mononuclear cells were present in the peripheral blood. A bone marrow biopsy specimen demonstrated myelofibrosis and diffuse infiltration of abnormal monoculear cells with a mature B cell phenotype. A bone marrow aspirate showed 29% abnormal mononuclear cells, which had an indented or folded nucleus and reticular nuclear chromatin. Moderate to strong tartarate-resistant acid phosphatase activity was detected in these cells. Although the cytoplasmic projections were poorly preserved in specimens stained with May-Giemsa, fresh preparations showed numerous slender cytoplasmic projections by phase-contrast microscopy. The hairy cells had the phenotype CD5-, CD10-, CD11c+, CD19+, CD20+, CD25+, lambda. The patient was diagnosed as having European-American-type hairy cell leukemia (HCL) without splenomegaly, which is quite rare in Japan. The value of phase-contrast microscopy for recognition of the hairy cells was emphasized. The patient was treated successfully with deoxycoformycin (DCF).

4
UI - 21431759
AU - Thaker H; Neilly IJ; Saunders PG; Magee JG; Snow MH; Ong EL
TI - Remember mycobacterial disease in hairy cell leukaemia (HCL).
SO - J Infect 2001 Apr;42(3):213-4
AD - Department of Infection and Tropical Medicine, University of Newcastle Medical School, Newcastle General Hospital, Newcastle upon Tyne NE4 6BE, UK.

5
UI - 84300326
AU - Culliton BJ
TI - Patient sues UCLA over patent on cell line.
SO - Science 1984 Sep 28;225(4669):1458

6
UI - 85012639
AU - Blakeslee S
TI - Patient sues for title to own cells.
SO - Nature 1984 Sep 20-26;311(5983):198

7
UI - 91131397
AU - Annas GJ
TI - Outrageous fortune: selling other people's cells.
SO - Hastings Cent Rep 1990 Nov-Dec;20(6):36-9
AD - Law, Medicine and Ethics Program, Boston University School of Medicine.

8
UI - 96084908
AU - Hinnie J; O'Reilly DS
TI - Hypocholesterolaemia in hairy cell leukemia.
SO - BMJ 1995 Nov 25;311(7017):1437-8

9
UI - 21416548
AU - Fujita H; Koharazawa H; Nishida H; Terada S; Morishita T; Kuroyama Y;
TI - Ohata M; Ishigatsubo Y [Successful treatment of hairy cell leukemia with pentostatin]
SO - Rinsho Ketsueki 2001 Jul;42(7):537-42
AD - Department of Hematology/Rheumatology, Shizuoka Red Cross Hospital.
A 45-year-old woman was admitted to our hospital in August, 1999. Laboratory data showed a white blood cell count of 5,050/microliter with 78% abnormal lymphocytes, hemoglobin 6.8 g/dl, platelets 4.8 x 10(4)/microliter, and soluble IL-2 receptor 97,600/ml. The abnormal cells were characterized by a hairy appearance under phase contrast microscopy, and showed strong tartrate-resistant acid phosphatase activity. Immunophenotype analysis revealed that these cells were positive for CD11c, CD19 and CD25, and negative for CD5. Bone marrow biopsy showed diffuse proliferation of hairy cells with moderate myelofibrosis. We diagnosed the patient as having European-American-type hairy cell leukemia. Pentostatin was administered at a dose of 5 mg/m2 weekly. After twelve doses, the peripheral blood data returned to the normal range with no hairy cells in the blood or bone marrow, although slight splenomegaly remained. The patient underwent splenectomy in December of the same year, and we were unable to find any hairy cells by histological and immunohistochemical examination. Although most patients with hairy cell leukemia in Japan have the Japanese variant, and the European-American type is rare, pentostatin is as effective as it is for European and American patients.

The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.

OncoLink Cancer Treatment and Resources

OncoLink I wish u knew...

Survivorship care can help cancer survivors live healthier, fuller lives after treatment. Read more.

Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet

Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies

Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer

Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults

OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews

Ask the Experts
Brown Bag Chat
Tracy's Corner

About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement